Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression.
Ammonium Compounds
/ chemistry
Antidepressive Agents
/ chemistry
Antineoplastic Agents
/ chemistry
Calcium
/ metabolism
Cell Proliferation
/ drug effects
Depression
/ drug therapy
Humans
MCF-7 Cells
Molecular Targeted Therapy
Neoplasms
/ drug therapy
Receptors, sigma
/ metabolism
Salts
/ chemistry
Sigma-1 Receptor
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 06 2020
08 06 2020
Historique:
received:
12
06
2019
accepted:
06
05
2020
entrez:
10
6
2020
pubmed:
10
6
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Sigma-1 and sigma-2 receptors are emerging therapeutic targets. We have identified that simple ammonium salts bind to these receptors and are effective in vivo. Radioligand binding assays were used to obtain structure-activity relationships of these salts. MTS assays were performed to determine their effect on growth in MCF7 and MDA-MB-486 cells. Anticancer properties were tested in NMRI mice transplanted with a fragment of mouse adenocarcinoma (MAC13). Antidepressant activity was tested using the forced-swim test and tail suspension tests. Dipentylammonium (K
Identifiants
pubmed: 32514120
doi: 10.1038/s41598-020-65849-6
pii: 10.1038/s41598-020-65849-6
pmc: PMC7280195
doi:
Substances chimiques
Ammonium Compounds
0
Antidepressive Agents
0
Antineoplastic Agents
0
Receptors, sigma
0
Salts
0
sigma-2 receptor
0
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9251Références
Martin, W. R. et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197, 517–32 (1976).
pubmed: 945347
Hanner, M. et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93, 8072–7 (1996).
pubmed: 8755605
doi: 10.1073/pnas.93.15.8072
Schmidt, H. R. et al. Crystal structure of the human sigma1 receptor. Nature 532, 527–30 (2016).
pubmed: 27042935
pmcid: 5550834
doi: 10.1038/nature17391
Fontanilla, D. et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323, 934–7 (2009).
pubmed: 19213917
pmcid: 2947205
doi: 10.1126/science.1166127
Alon, A. et al. Identification of the gene that codes for the sigma2 receptor. Proc Natl Acad Sci USA 114, 7160–7165 (2017).
pubmed: 28559337
doi: 10.1073/pnas.1705154114
Maurice, T. & Su, T. P. The pharmacology of sigma-1 receptors. Pharmacol Ther 124, 195–206 (2009).
pubmed: 19619582
pmcid: 2785038
doi: 10.1016/j.pharmthera.2009.07.001
Safrany, S. T. & Brimson, J. M. Are fluoxetine’s effects due to sigma-1 receptor agonism? Pharmacol Res 113, 707–708 (2016).
pubmed: 27262678
doi: 10.1016/j.phrs.2016.05.031
Werling, L. L., Keller, A., Frank, J. G. & Nuwayhid, S. J. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 207, 248–57 (2007).
pubmed: 17689532
doi: 10.1016/j.expneurol.2007.06.013
Vilner, B. J., John, C. S. & Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Research 55, 408–13 (1995).
pubmed: 7812973
Caveliers, V. et al. Labelled sigma receptor ligands: can their role in neurology and oncology be extended? Eur J Nucl Med 28, 133–5 (2001).
pubmed: 11303881
doi: 10.1007/s002590000368
Spruce, B. A. et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Research 64, 4875–86 (2004).
pubmed: 15256458
doi: 10.1158/0008-5472.CAN-03-3180
Wang, L. et al. Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation. Invest Ophthalmol Vis Sci 46, 1403–8 (2005).
pubmed: 15790908
doi: 10.1167/iovs.04-1209
Baxendale, I. R., Hayward, J. J., Ley, S. V. & Tranmer, G. K. Pharmaceutical strategy and innovation: An academics perspective. Chemmedchem 2, 768–788 (2007).
pubmed: 17458911
doi: 10.1002/cmdc.200700008
Ablordeppey, S., Fischer, J. B. & Glennon, R. A. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg Med Chem 8, 2105–11 (2000).
pubmed: 11003156
doi: 10.1016/S0968-0896(00)00148-6
Glennon, R. A. et al. Structural features important for sigma 1 receptor binding. J Med Chem 37, 1214–9 (1994).
pubmed: 8164264
doi: 10.1021/jm00034a020
Fujimura, K. et al. Synthesis, structure and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines. Bioorg Med Chem 5, 1675–83 (1997).
pubmed: 9313869
doi: 10.1016/S0968-0896(97)00093-X
Brimson, J. M., Safrany, S. T., Qassam, H. & Tencomnao, T. Dipentylammonium Binds to the Sigma-1 Receptor and Protects Against Glutamate Toxicity, Attenuates Dopamine Toxicity and Potentiates Neurite Outgrowth in Various Cultured Cell Lines. Neurotox Res 34, 263–272 (2018).
pubmed: 29589276
doi: 10.1007/s12640-018-9883-5
Ramachandran, S. et al. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol 609, 19–26 (2009).
pubmed: 19285059
pmcid: 3194046
doi: 10.1016/j.ejphar.2009.03.003
Brimson, J. M., Brown, C. A. & Safrany, S. T. Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor. Br J Pharmacol 164, 772–80 (2011).
pubmed: 21486275
pmcid: 3188898
doi: 10.1111/j.1476-5381.2011.01417.x
Abbas, H., et al. Hazards of Using Masking Protocols When Performing Ligand Binding Assays: Lessons From the Sigma-1 and Sigma-2 Receptors. Frontiers in Pharmacology 11 (2020).
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23, 3–25 (1997).
doi: 10.1016/S0169-409X(96)00423-1
Clark, D. E. In silico prediction of blood-brain barrier permeation. Drug Discovery Today 8, 927–933 (2003).
pubmed: 14554156
doi: 10.1016/S1359-6446(03)02827-7
Porsolt, R. D., Bertin, A. & Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229, 327–36 (1977).
pubmed: 596982
Steru, L., Chermat, R., Thierry, B. & Simon, P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85, 367–70 (1985).
doi: 10.1007/BF00428203
Shank, R. P. et al. McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247, 1032–8 (1988).
pubmed: 2905001
Chalon, S. et al. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4’-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291, 648–54 (1999).
pubmed: 10525084
Bonisch, H. The transport of (+)-amphetamine by the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch Pharmacol 327, 267–72 (1984).
pubmed: 6514010
doi: 10.1007/BF00506235
Bibby, M. C., Double, J. A. & Mughal, M. A. Effects of Nandrolone Decanoate on the Toxicity and Anti-Tumor Action of Ccnu and Fu in Murine Tumors. British Journal of Cancer 44, 572–577 (1981).
pubmed: 7295514
pmcid: 2010805
doi: 10.1038/bjc.1981.228
Gund, T. M., Floyd, J. & Jung, D. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations. Journal of Molecular Graphics & Modelling 22, 221–230 (2004).
doi: 10.1016/j.jmgm.2003.08.001
Spassova, M. A. & Lu, Z. Coupled ion movement underlies rectification in an inward-rectifier K+ channel. Journal of General Physiology 112, 211–221 (1998).
pubmed: 9689028
doi: 10.1085/jgp.112.2.211
Sobolevsky, A. I., Koshelev, S. G. & Khodorov, B. I. Probing of NMDA channels with fast blockers. Journal of Neuroscience 19, 10611–10626 (1999).
pubmed: 10594045
doi: 10.1523/JNEUROSCI.19-24-10611.1999
Hong, W. & Werling, L. L. Binding of sigma receptor ligands and their effects on muscarine-induced Ca
pubmed: 11834244
doi: 10.1016/S0014-2999(01)01606-5
Ochoa, E. L., Chattopadhyay, A. & McNamee, M. G. Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators. Cell Mol Neurobiol 9, 141–78 (1989).
pubmed: 2663167
doi: 10.1007/BF00713026
Birdsong, W. T. et al. Increased agonist affinity at the mu-opioid receptor induced by prolonged agonist exposure. J Neurosci 33, 4118–27 (2013).
pubmed: 23447620
pmcid: 3711766
doi: 10.1523/JNEUROSCI.4187-12.2013
Chang, Y. et al. Desensitization mechanism of GABA receptors revealed by single oocyte binding and receptor function. J Neurosci 22, 7982–90 (2002).
pubmed: 12223551
pmcid: 6758118
doi: 10.1523/JNEUROSCI.22-18-07982.2002
Sabino, V. et al. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 198, 472–6 (2009).
pubmed: 19100292
doi: 10.1016/j.bbr.2008.11.036
Urani, A. et al. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298, 1269–79 (2001).
pubmed: 11504830
Galli, A. et al. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 198, 2197–212 (1995).
pubmed: 7500004
Ramamoorthy, S. et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90, 2542–6 (1993).
pubmed: 7681602
doi: 10.1073/pnas.90.6.2542
Aydar, E., Palmer, C. P., Klyachko, V. A. & Jackson, M. B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34, 399–410 (2002).
pubmed: 11988171
doi: 10.1016/S0896-6273(02)00677-3
Dhir, A. & Kulkarni, S. K. Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett 420, 204–8 (2007).
pubmed: 17532136
doi: 10.1016/j.neulet.2007.04.055
Kulkarni, S. K. & Dhir, A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 589, 163–72 (2008).
pubmed: 18585703
doi: 10.1016/j.ejphar.2008.05.043
Bibby, M. C. et al. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 78, 539–46 (1987).
pubmed: 3546909
Brimson, J. M. University of Bath (2010).
Abbas, H. University of Wolverhampton (2018).